Phentermine Returns for Weight Loss, But at a Low Dose - Medscape News

May 25, 2012 (Lyon, France) — The combination of low-dose phentermine plus extended-release topiramate (Qnexa, Vivus) might help overweight and obese people lose weight, regardless of their obesity-related risk or the extent of their comorbidities.

Topiramate linked to angle-closure glaucoma - Xagena Medical News

Topiramate ( Topamax ) is an antiepileptic indicated for either monotherapy or add-on therapy in adults and in children aged two years and over; and for the prophylaxis of migraine in adults. Topiramate has been rarely associated with the development of ...

ECO: New weight loss drug effective in advanced obesity - medicalxpress.com

(HealthDay) -- A new combination treatment of controlled-release phentermine/topiramate (PHEN/TPM CR) leads to significantly greater weight loss than a placebo even in individuals with significant obesity-related comorbidities, according to a ...

Anti-obesity treatments reduce blood pressure in 2 studies - SmartBrief

Combination therapy with extended-release phentermine/topiramate slowed progression from prehypertension to hypertension, lowered blood pressure and reduced weight in one study. In the other study, laparoscopic adjustable gastric banding enabled about 25% ...

New Weight-Loss Drug Shows Promise in Trial - US News and World Report

Volunteers who took Qnexa, a combination of the drugs phentermine and topiramate, experienced substantial weight loss, even if they had many weight-related health problems, the study found. The findings were reported this week during the ...

Drugs Help Tailor Alcoholism Treatment - New York Times

Despite some unpleasant side effects (fatigue, confusion, nausea), topiramate has become a commonly prescribed off-label treatment for alcoholism. Baclofen, an antispasm medication, is also sometimes prescribed off-label for alcoholics ...

An Endless Quest for Weight-Loss Pills - New York Times Blogs

Lauer, was one of only two members of a 22-member Food and Drug Administration panel who earlier this year voted against approval of the new weight-loss drug Qnexa, a combination of phentermine and topiramate, an epilepsy drug with an ...

Vivus Will Plummet If Qnexa Fails - Seekingalpha.com

Qnexa, is a combination of phentermine, (the "beneficial" part of now extinct fen-phen) and topiramate an ingredient which controls the brain receptors associated with hunger. Both ingredients are currently available in generic formulations and already ...

FDA Panel to Mull Weight-Loss Drug -- Again - MedPage Today

The FDA is expected to make a decision on Qnexa-- a low-dose combination of phentermine and topiramate -- in July. Like lorcaserin, Qnexa was at first rejected by the FDA, but Vivus Inc., the manufacturer of Qnexa, submitted new data on the drug ...

Is Arena Pharmaceuticals (ARNA) a Done Deal? Plus an Update on Obesity Drug Stocks Orexigen Therapeutics (OREX) & VIVUS (VVUS) - Small Cap Network

This means that VIVUS probably has a first mover advantage when it comes to obesity drugs (Note: Qnexa is a combination of two drugs, phentermine and topiramate, both of which has been approved for obesity treatment separately plus VVUS is still in early ...